Immunocore Holdings PLC (STU:6YG)

Q2 2025 Immunocore Holdings PLC Earnings Call Transcript

Aug 7, 2025 / 12:00 PM GMT

Release Date Price: €27

Transcript 8-K10-Q

Key Points

Positve

Immunocore Holdings PLC (IMCR) reported a strong start to 2025 with $192 million in KimTrac revenue, marking a 32% year-over-year growth.
KimTrac has been launched in 28 countries and approved in 39, showcasing significant global expansion.
The company is advancing three phase 3 clinical trials in melanoma, with promising enrollment and potential to address unmet medical needs.
Immunocore Holdings PLC (IMCR) maintains a strong balance sheet with $883 million in cash and marketable securities, enabling continued investment in R&D.
The company is on track to file a CTA for its autoimmune candidates in type 1 diabetes by the end of 2025, with clinical trials expected to start in 2026.

Negative

Despite strong growth, Immunocore Holdings PLC (IMCR) anticipates more modest growth moving forward as KimTrac enters its fourth year on the market.
Operating expenses have increased due to ongoing investments in phase 3 trials and early-stage research programs.
There is uncertainty regarding the timing of data readouts from ongoing trials, which are event-driven and subject to variability.
The company faces potential challenges from evolving FDA requirements and competitive pressures in the melanoma treatment space.
Revenue from international regions outside the US and EU showed variability, highlighting potential challenges in maintaining consistent growth across all markets.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMCR.OQ - Immunocore Holdings PLC
Q2 2025 Immunocore Holdings PLC Earnings Call
Aug 07, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Immunoor conference call and webcast. At this time, all participants are to listen-only mode. If anyone should require operator assistance, please press 0 on your telephone keypad. A question and answer session will follow the formal presentation, and you may be placed in the question queue any time by pressing 1 on your telephone keypad. As a reminder, this conference is being recorded. It's not my pleasure to turn the call over to Clayton Robertson and best relations. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.